Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-033 Phase I/II Study in Advanced Malignant Tumors
CTR20230698Phase 2Completed
- Sponsor
- Leads Biolabs
- Start
- Apr 2023
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LBL-033 in Non-hematologic malignancy, sponsored by Leads Biolabs. Started Apr 2023; status: completed.
02
Drugs
LBL-033
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on CTR20230698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230698.